Related Experiment Video

Updated: Sep 22, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K

PGM1 suppresses colorectal cancer cell migration and invasion by regulating the PI3K/AKT pathway

Zhewen Zheng1, Xue Zhang2, Jian Bai3

  • 1Department of Radiation Oncology and Medical Oncology, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuchang District, Wuhan, Hubei, People's Republic of China.

Cancer Cell International
|May 25, 2022
PubMed
Abstract

Insights

Phosphoglucomutase 1 (PGM1) suppresses colorectal cancer (CRC) progression by inhibiting cell proliferation and promoting apoptosis. Targeting PGM1 may offer a new therapeutic strategy for CRC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Phosphoglucomutase 1 (PGM1) is implicated in cancer, but its specific role in colorectal cancer (CRC) was previously unknown.
  • This study investigated the functions and underlying mechanisms of PGM1 in the context of CRC.

Purpose of the Study:

  • To elucidate the biological role and functional mechanisms of PGM1 in colorectal cancer (CRC).
  • To determine if PGM1 can be a potential therapeutic target for CRC treatment.

Main Methods:

  • Utilized TCGA-COAD dataset mining and computational biology to identify PGM1 as a differentially expressed gene.
  • Assessed PGM1 expression in CRC tissues using qRT-PCR, western blotting, and immunohistochemistry.
  • Evaluated PGM1's functional impact on CRC cell proliferation, apoptosis, cell cycle, migration, and invasion in vitro and in vivo.

Main Results:

  • PGM1 expression was significantly reduced in CRC tissues, correlating with poorer CRC pathology and overall survival.
  • PGM1 knockdown enhanced CRC cell proliferation and colony formation while inhibiting apoptosis and cell cycle arrest.
  • PGM1 overexpression demonstrated opposing effects, suppressing CRC progression in vitro and in vivo, linked to the PI3K/AKT pathway.

Conclusions:

  • PGM1 acts as a tumor suppressor in colorectal cancer, inhibiting tumor progression through the PI3K/AKT signaling pathway.
  • These findings highlight PGM1 as a promising therapeutic target for colorectal cancer interventions.
Keywords:
ApoptosisColorectal cancerPhosphoglucomutase 1PrognosisProliferation

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K
In vitro Organoid Culture of Primary Mouse Colon Tumors07:33

In vitro Organoid Culture of Primary Mouse Colon Tumors

Published on: May 17, 2013

35.3K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.2K